Table 1.
Baseline characteristics of patients receiving first allogeneic transplant between 2008 and 2017
| Characteristic | N (%) |
|---|---|
| Number of patients | 21574 |
| Number of centers | 255 |
| Age, median (range) | 55 (18–88) |
| Male | 12672 (59) |
| Race | |
| Caucasian | 15993 (74) |
| Ethnicity | |
| Not Hispanic or Latino | 17962 (83) |
| KPS 90–100 | 12833 (59) |
| HCT-CI (minus pulmonary comorbidity) | |
| 0 | 6018 (28) |
| 1 | 3001 (14) |
| 2 | 2884 (13) |
| 3 | 3712 (17) |
| 4 | 2262 (10) |
| 5+ | 3231 (15) |
| Pulmonary comorbidity (based on HCT-CI) | |
| Moderate | 5163 (24) |
| Severe | 3242 (15) |
| History of mechanical ventilation | 646 (3) |
| History of smoking cigarettes | 8541 (40) |
| Disease indication | |
| AML | 8003 (37) |
| MDS/MPN | 6044 (28) |
| ALL | 2362 (11) |
| Lymphoma | 2081 (10) |
| Non-malignant disease | 1107 (5) |
| CML | 722 (3) |
| CLL | 696 (3) |
| MM/PCD | 300 (1) |
| Other malignant disease | 259 (1) |
| Refined-Disease Risk Index groups | |
| Low | 2061 (10) |
| Intermediate | 10846 (50) |
| High | 5955 (28) |
| Very high | 745 (3) |
| Prior autologous transplant | 1277 (6) |
| Donor type | |
| Matched unrelated | 8270 (38) |
| HLA-identical sibling | 5576 (26) |
| Cord blood | 2911 (13) |
| Haploidentical | 1978 (9) |
| Mismatched unrelated | 1891 (9) |
| Other | 900 (5) |
| Graft source | |
| Peripheral blood | 15335 (71) |
| Bone marrow | 3328 (15) |
| Umbilical cord blood | 2911 (13) |
| Conditioning regimen intensity | |
| MAC | 10665 (49) |
| RIC | 7242 (34) |
| NMA | 3667 (17) |
| TBI and intensity | |
| Myeloablative TBI | 4285 (20) |
| Non-myeloablative TBI | 4109 (19) |
| GVHD prophylaxis | |
| TAC + MMF or MTX or other | 13256 (61) |
| CSA + MMF or MTX | 3837 (18) |
| ptCy | 2246 (10) |
| Ex-vivo T-cell depletion or CD34 selection | 694 (3) |
| ATG/Alemtuzumab | |
| ATG alone | 5885 (27) |
| Alemtuzumab alone | 656 (3) |
| Year of transplant | |
| 2008–2013 | 10888 (51) |
| 2014–2017 | 10686 (49) |
| Follow-up of survivors, median (range) | 49 (3–131) |
Abbreviations: alloHCT = allogeneic hematopoietic cell transplantation; KPS = Karnofsky Performance Score, HCT-CI = Hematopoietic Cell Transplantation-Comorbidity Index; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; MPN = myeloproliferative neoplasm; NHL = non-Hodgkin’s lymphoma; CLL = chronic lymphocytic leukemia; PCD = plasma cell disorders; MAC = myeloablative conditioning; RIC = reduced intensity conditioning; NMA = non-myeloablative conditioning; TBI = total body irradiation; Cy = cyclophosphamide; Flu = fludarabine; Bu = busulfan; Mel = melphalan; TAC = tacrolimus; MTX = methotrexate; MMF = mycophenolate mofetil; ptCy = post-transplant cyclophosphamide; ATG = anti-thymocyte globulin
Other donors included any matched related (not siblings), 1-locus mis-matched related donors, and cases with related donors who do not have HLA-matching information.